Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer

Efficacy of PD-1-inhibitor-based Combination Therapy in Patients With Metastatic Colorectal Cancer

Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.

Inclusion Criteria:

• patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment
• patients with identified genomic status

Exclusion Criteria:

• patients who received immune monotherapy
• patients who stopped treatment for any reason without identified response assessment.